DVAX Dynavax Technologies

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of novel vaccines and immuno-oncology therapeutics. The firm focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.
Company profile
Ticker
DVAX
Exchange
Website
CEO
Ryan Spencer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
330728374
DVAX stock data
()
News
Valneva's COVID-19 Vaccine Candidate Using Dynavax's Adjuvant Shows Positive Interim Results
6 Apr 21
The Daily Biotech Pulse: Illumina Lights Up, Cara Soars On Index Inclusion, Novavax Starts Crossover Vaccine Study, Turning Point Data Readout
6 Apr 21
Dynavax Announces Valneva SE Reported Results From Part A Of Phase 1/2 Trial Of Its COVID-19 Vaccine Using Dynavax's CpG 1018 Adjuvant; Valneva Plans To Commence Phase 3 Trial By End Of Apr.
6 Apr 21
The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping
24 Mar 21
Clover Biopharmaceuticals And Dynavax Announce First Participants Dosed In SPECTRA Global Phase 2/3 Clinical Trial For Adjuvanted S-Trimer COVID-19 Vaccine Candidate
24 Mar 21
Press releases
Positive Phase 1/2 Results for Valneva's Inactivated COVID-19 Vaccine Candidate Using Dynavax's CpG 1018™ Adjuvant
6 Apr 21
Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
6 Apr 21
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 Apr 21
Effective Diagnostics Help to Tame the Spread of the Pandemic
24 Mar 21
Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate
24 Mar 21
Investment data
Securities sold
Number of investors
Calendar
25 Feb 21
18 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 32.31M | 32.31M | 32.31M | 32.31M | 32.31M | 32.31M |
Cash burn (monthly) | 201.33K | 649.17K | 3.97M | 5.7M | 5.25M | 7.69M |
Cash used (since last report) | 728.68K | 2.35M | 14.35M | 20.62M | 18.99M | 27.82M |
Cash remaining | 31.58M | 29.96M | 17.96M | 11.69M | 13.32M | 4.49M |
Runway (months of cash) | 156.9 | 46.2 | 4.5 | 2.1 | 2.5 | 0.6 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 21 | David F Novack | Common Stock | Sell | Dispose S | No | Yes | 9.92 | 20,000 | 198.4K | 117,399 |
12 Mar 21 | Janssen Robert | Common Stock | Gift | Dispose G | No | No | 0 | 1,000 | 0 | 86,861 |
2 Mar 21 | Justin Burgess | Common Stock | Sell | Dispose S | No | No | 8.82 | 1,165 | 10.28K | 7,010 |
1 Mar 21 | Kelly MacDonald | Stock Option Common Stock | Grant | Aquire A | No | No | 8.9 | 350,000 | 3.12M | 350,000 |
1 Mar 21 | Justin Burgess | Common Stock | Sell | Dispose S | No | No | 8.88 | 1,633 | 14.5K | 8,175 |
1 Mar 21 | Justin Burgess | Common Stock | Sell | Dispose S | No | No | 8.88 | 1,325 | 11.77K | 9,808 |
1 Mar 21 | Justin Burgess | Common Stock | Option exercise | Aquire M | No | No | 0 | 2,839 | 0 | 11,133 |
1 Mar 21 | Justin Burgess | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 2,839 | 0 | 0 |
26 Feb 21 | Justin Burgess | Common Stock | Option exercise | Aquire M | No | No | 0 | 3,906 | 0 | 8,294 |
26 Feb 21 | Justin Burgess | Common Stock | Option exercise | Aquire M | No | No | 0 | 3,167 | 0 | 4,388 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
64.6% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 142 |
Opened positions | 11 |
Closed positions | 34 |
Increased positions | 53 |
Reduced positions | 43 |
13F shares |
Current |
---|---|
Total value | 467.07M |
Total shares | 73.21M |
Total puts | 762.2K |
Total calls | 568.3K |
Total put/call ratio | 1.3 |
Largest owners |
Shares | Value |
---|---|---|
FHI Federated Hermes | 11.95M | $53.16M |
STT State Street | 10.89M | $48.45M |
BLK Blackrock | 8.19M | $36.44M |
Chicago Capital | 5.78M | $25.73M |
Vanguard | 5.11M | $22.75M |
Avidity Partners Management | 4M | $17.8M |
Partner Fund Management | 2.94M | $13.07M |
Blair William & Co | 2.18M | $9.72M |
GS Goldman Sachs | 2.03M | $9.06M |
Rock Springs Capital Management | 1.65M | $7.34M |
Financial report summary
?Competition
Pfizer • AMGEN • VBI Vaccines • VBI Vaccines • Celgene • Idera Pharmaceuticals • Astrazeneca • Roche • Novavax • AgenusContent analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
accuracy, acellular, alter, anesthesiologist, Assent, bargaining, Biden, BMGF, bond, booster, Brexit, bridge, broader, cancellation, capture, CEO, CEPI, cGMP, charitable, CHMP, Coalition, commerce, compliant, composition, compound, constitutionality, coupled, COVID, CPRA, creative, cutoff, cybersecurity, dedicate, differentially, diphtheria, disproportionate, distancing, drastically, driver, EEA, eighty, elderly, exacerbated, expiry, explained, exploit, factor, felt, fine, flu, forensic, forgivable, forgiven, Foundation, fundamental, GASC, gradually, half, harbor, harder, headwind, highlighted, Importantly, influenza, inJanuary, intensified, inter, Internationally, invoice, invoked, IPR, Israel, JUSTIN, Kingdom, labor, lawfully, leadership, length, lifted, Medicinal, Melinda, mix, Moderna, nationwide, nondiscriminatory, nurse, offsite, online, onsite, outpace, output, paradiso, paused, peter, PGR, pharmacy, philanthropic, phishing, phone, polarized, pose, posed, pre, predecessor, preferential, premier, promptly, proportion, proportional, punitive, question, reactogenicity, recession, reconsider, reliant, remote, remotely, reorder, repay, replenished, restoration, revealed, robust, Royal, scam, science, Scotland, sequester, seroprotection, shelter, Shield, shift, shifting, shipment, stall, stiff, strict, Supreme, Surefire, surety, survey, Switzerland, talent, Tdap, tender, tenure, tie, uninterrupted, unknown, unnecessary, unredacted, unrelated, unsecured, unusual, viable, video, virtual, visit, wholly, worsening
Removed:
accommodate, allocable, arnold, attestation, autoimmune, bearing, broadening, charter, complaint, complying, david, declare, deployed, directed, Double, eliminating, generic, Helix, immunotherapy, implied, inflammatory, interference, invent, investigational, licensee, listed, lowering, MAA, necessarily, nominating, oncology, oronsky, outplacement, paragraph, pipeline, posted, PPACA, preceding, premium, print, PTO, retrospective, Trademark, Unaudited, writing
Financial reports
10-K
2020 FY
Annual report
25 Feb 21
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
7 May 20
10-K
2019 FY
Annual report
11 Mar 20
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
7 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
26 Feb 19
10-Q
2018 Q3
Quarterly report
6 Nov 18
Current reports
8-K
Other Events
6 Apr 21
8-K
Dynavax Announces Fourth Quarter and Full Year 2020 Financial Results
25 Feb 21
8-K
Dynavax Announces European Commission Marketing Authorization for HEPLISAV B®, a 2 Dose Adult Hepatitis B Adjuvanted Vaccine
19 Feb 21
8-K
Entry into a Material Definitive Agreement
1 Feb 21
8-K
Departure of Directors or Certain Officers
21 Jan 21
8-K
Departure of Directors or Certain Officers
12 Jan 21
8-K
Other Events
7 Jan 21
8-K
Dynavax Announces Third Quarter 2020 Financial Results
5 Nov 20
8-K
Departure of Directors or Certain Officers
24 Sep 20
8-K
Other Events
14 Sep 20
Registration and prospectus
S-8
Registration of securities for employees
25 Feb 21
S-3ASR
Automatic shelf registration
6 Aug 20
S-8
Registration of securities for employees
6 Aug 20
S-3ASR
Automatic shelf registration
2 Jul 20
424B5
Prospectus supplement for primary offering
22 May 20
424B5
Prospectus supplement for primary offering
21 May 20
POS AM
Prospectus update (post-effective amendment)
11 Mar 20
S-8
Registration of securities for employees
13 Aug 19
424B5
Prospectus supplement for primary offering
8 Aug 19
424B5
Prospectus supplement for primary offering
7 Aug 19
Proxies
DEFA14A
Additional proxy soliciting materials
16 Apr 21
DEF 14A
Definitive proxy
16 Apr 21
DEFA14A
Additional proxy soliciting materials
22 May 20
DEFA14A
Additional proxy soliciting materials
17 Apr 20
DEF 14A
Definitive proxy
17 Apr 20
PRE 14A
Preliminary proxy
7 Apr 20
DEFA14A
Additional proxy soliciting materials
23 May 19
DEF 14A
Definitive proxy
22 Apr 19
DEF 14A
Definitive proxy
19 Apr 18
DEF 14A
Definitive proxy
9 Jul 17
Other
CT ORDER
Confidential treatment order
3 Mar 21
CT ORDER
Confidential treatment order
30 Sep 20
EFFECT
Notice of effectiveness
1 May 20
CT ORDER
Confidential treatment order
7 Nov 19
CT ORDER
Confidential treatment order
16 Apr 19
CT ORDER
Confidential treatment order
15 Apr 18
CORRESP
Correspondence with SEC
6 Jul 17
UPLOAD
Letter from SEC
6 Jul 17
UPLOAD
Letter from SEC
5 Jul 17
EFFECT
Notice of effectiveness
25 Apr 17
Ownership
4
DYNAVAX TECHNOLOGIES / David F Novack ownership change
2 Apr 21
4/A
DYNAVAX TECHNOLOGIES / Justin Burgess ownership change
26 Mar 21
4
DYNAVAX TECHNOLOGIES / Robert Janssen ownership change
12 Mar 21
4
DYNAVAX TECHNOLOGIES / Kelly MacDonald ownership change
2 Mar 21
3
DYNAVAX TECHNOLOGIES / Kelly MacDonald ownership change
2 Mar 21
4
DYNAVAX TECHNOLOGIES / Justin Burgess ownership change
2 Mar 21
4
DYNAVAX TECHNOLOGIES / Ryan Spencer ownership change
23 Feb 21
SC 13G
DYNAVAX TECHNOLOGIES / Chicago Capital ownership change
23 Feb 21
SC 13G/A
DYNAVAX TECHNOLOGIES / FEDERATED HERMES ownership change
12 Feb 21
SC 13G
DYNAVAX TECHNOLOGIES / STATE STREET ownership change
11 Feb 21
Patents
GRANT
Utility
Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
24 Aug 20
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
GRANT
Utility
Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof
27 Jul 20
The present disclosure relates to cleavable conjugates (for example, particle-based or antibody-based conjugates) of TLR7/8 agonists (for example, 1H-imidazo[4,5-c]quinoline derivatives) containing a conjugation linker, a cleavable linker, and a self-eliminating linker.
APP
Utility
Alkyl Chain Modified Imidazoquinoline TLR7/8 Agonist Compounds and Uses Thereof
24 Jun 20
Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses.
GRANT
Utility
Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof
13 Apr 20
Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses.
GRANT
Utility
Branched chimeric compounds, and methods of use thereof
3 Feb 20
The present disclosure relates to branched and linear chimeric compounds containing both nucleic acid and non-nucleic acid moieties, as well as to polynucleotides.
Transcripts
2020 Q4
Earnings call transcript
26 Feb 21
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
6 Aug 20
2020 Q1
Earnings call transcript
7 May 20
2019 Q3
Earnings call transcript
6 Nov 19
2019 Q2
Earnings call transcript
7 Aug 19
2019 Q1
Earnings call transcript
8 May 19
2018 Q4
Earnings call transcript
26 Feb 19
2018 Q3
Earnings call transcript
5 Nov 18
2018 Q2
Earnings call transcript
6 Aug 18
Reddit threads
Portfolio Questions for We Options Traders
3 Apr 21
What Are Your Moves Tomorrow, Mar-19-2021
18 Mar 21
I can talk to a bot that analyzes stocks.
12 Mar 21
Call options expirations questions
26 Feb 21
Daily Discussion Thread - February 25th, 2021
25 Feb 21
Daily Discussion Thread - February 24th, 2021
24 Feb 21
Daily Discussion Thread - February 23rd, 2021
23 Feb 21
$ADMA Research/Light DD
16 Feb 21
Daily Plays - February 16, 2021
16 Feb 21
r/Stocks Discuss Overlooked Stocks Friday - Feb 12, 2021
12 Feb 21